Defining the Problem of Treating the Patient with Hypertension and Arthritis Pain

American Journal of Medicine

Volumn 122, Issue 5 SUPPL., 2009, Pages

  White, William B ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Anti inflammatory; Blood pressure; Hypertension; NSAIDs; Osteoarthritis

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IBUPROFEN; INDOMETACIN; LISINOPRIL; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROTON PUMP INHIBITOR; ROFECOXIB;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MORBIDITY; OBSERVATIONAL STUDY; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; STATISTICAL SIGNIFICANCE; STROKE; SYSTOLIC BLOOD PRESSURE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; HUMANS; HYPERTENSION; MIDDLE AGED; OSTEOARTHRITIS;

EID: 64849106874     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.03.002     Document Type: Article

References (30)

1. Singh G., Miller J.D., Lee F.H., Pettitt D., and Russell M.W. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care 8 suppl (2002) S383-S391
2. Caporali R., Cimmino M.A., Sarzi-Puttini P., et al. Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists. Semin Arthritis Rheum 35 suppl 1 (2005) 31-37
3. White W.B. Hypertension associated with therapies to treat arthritis and pain. Hypertension 44 (2004) 123-124
4. Pope J.E., Anderson J.J., and Felson D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153 (1993) 477-484
5. Johnson A.G., Nguyen T.V., and Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure?. A meta-analysis. Ann Intern Med 121 (1994) 289-300
6. Grover S.A., Coupal L., and Zowall H. Treating osteoarthritis with cyclooxygenase-2 specific inhibitors: what are the benefits of avoiding blood pressure destabilization?. Hypertension 45 (2005) 92-97
7. White W.B. Benefits of antihypertensive therapy in older patients with hypertension. Arch Intern Med 160 (2000) 149-150
8. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high CV risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 19 (2004) 363:2022-2031.
9. Brater D.C. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 107 (1999) 65S-70S
10. Whelton A., Schulman G., Wallemark C., et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 160 (2000) 1465-1470
11. Whelton A., White W.B., Bello A.E., Puma J.A., Fort J.G., and SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90 (2002) 959-963
12. Morgan T.O., Anderson A., and Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 13 (2000) 1161-1167
13. Solomon D.H., Schneeweiss S., Levin R., and Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 44 (2004) 140-145
14. Qi Z., Hao C.M., Langenbach R.I., et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 110 (2002) 61-69
15. Hermann M., Camici G., Fratton A., et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 108 (2003) 2308-2311
16. Hermann H., Shaw S., Kiss E., et al. Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 45 (2005) 193-197
17. White W.B., Kent J., Taylor A., Verburg K.M., Lefkewith J.B., and Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 39 (2002) 929-934
18. Izhar M., Alausa T., Folker A., Hunz G.E., and Bakris G.L. Effects of COX-inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics. Hypertension 43 (2004) 574-577
19. Klassen D.K., Jane L.H., Young D.Y., and Peterson C.A. Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. Am J Hypertens 8 (1995) 146-153
20. Sowers J.R., White W.B., Pitt B., et al., Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes. Arch Intern Med 165 (2005) 161-168
21. Mamdani M, Juurlink DN, Lee DS, et al. Cyclooxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 363:1751-1756.
22. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. JAMA 284 (2000) 1247-1255
23. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
24. White W.B., West C.R., Borer J.S., et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 99 (2007) 91-98
25. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke. BMJ 308 (1994) 81-106
26. Solomon S.D., Wittes J., Finn P.V., et al., Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117 (2008) 2104-2113
27. Farkouh M.E., Kirshner H., Harrington R.A., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364 (2004) 675-684
28. Cannon C.P., Curtis S.P., FitzGerald G.F., et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison in 34,701 patients. Lancet 368 (2006) 1771-1781
29. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenases: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA 296 (2006) 1633-1644
30. Chan A.T., Manson J.E., Albert C.M., et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113 (2006) 1578-1587